Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 12/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053182 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2NR1H3SMN1; SMN2GPR119 | |
| SCHEMBL7058265 | 0.83 | NR1H3 (0.45) | HSD17B10NR1H2NR1H3MEN1KMT2A | |
| SCHEMBL17439222 | 0.82 | GPR119 (0.45) | NR1H2NR1H3GPR119 | |
| SCHEMBL17439221 | 0.82 | GPR119 (0.45) | NR1H2NR1H3GPR119 | |
| SCHEMBL26673612 | 0.81 | ALDH1A1 (0.52) | NR1H2NR1H3 | |
| SCHEMBL20791294 | 0.80 | HSD17B10 (0.38) | HSD17B10NR1H2NR1H3SMN1; SMN2GPR119 | |
| SCHEMBL20791297 | 0.80 | HSD17B10 (0.38) | HSD17B10NR1H2NR1H3SMN1; SMN2GPR119 | |
| SCHEMBL22227 | 0.79 | HSD17B10 (0.51) | HSD17B10NR1H2SMN1; SMN2GPR119MEN1 | |
| SCHEMBL2364954 | 0.79 | HSD17B10 (0.51) | HSD17B10NR1H2SMN1; SMN2GPR119MEN1 | |
| SCHEMBL6625172 | 0.79 | HSD17B10 (0.48) | HSD17B10NR1H2NR1H3SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | disclosed |
| EP-1959951-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007063012-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HSD17B10 2485/4885NR1H2 2419/4885NR1H3 2328/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885NR1H2 3775/4885NR1H3 3875/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885NR1H2 3775/4885NR1H3 3875/4885 |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | HSD17B10 138/4885NR1H2 54/4885NR1H3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.